Title: A phase II study investigating preoperative bintrafusp alfa in operable urothelial carcinoma of the bladder
Disease site: Bladder cancer
Status: Closed

Trial Design: Open-label, international, multi-centre, window of opportunity phase II trial that aims to evaluate the effects of short-term preoperative therapy with bintrafusp alfa in patients with histologically confirmed urothelial carcinoma requiring radical cystectomy with bilateral pelvic lymph node dissection. Eligible patients will receive 4 doses of bintrafusp alfa (1200mg flat dose) at 14 day intervals before undergoing radical surgery. Patients will attend study visits at 6, 12 and 24 weeks following their surgery. After the 24-week post-surgical visit, patients will enter a follow up phase during which they will be contacted annually for 2 years after their surgery to collect survival and disease status data. The efficacy of bintrafusp alfa will be assessed on CT/MRI scan images and tumour tissue samples collected at baseline and after treatment with bintrafusp alfa.

Trial details

Chief Investigator: Prof T. Powles
Trial contact: NCT04878250
EudraCT: 2020-004223-16
Sponsor: Queen Mary University of London
Participating countries: UK, Spain, France
Source of funding: Merck Healthcare KGaA

Clinical Trial Portfolio

Click here to to see a list of our clinical trials that are currently in set up or those that are open to recruitment.